Photocure ASA
0IMT.L
London Stock Exchange59.20
NOK
-0.55
- -
Photocure ASA
0IMT.L
(London Stock Exchange)
Recent
price
59.20
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Photocure ASA (Ticker: 0IMT.L) develops and commercializes photodynamic technologies for the treatment of cancer and other diseases. The company offers Cevira, a hexylaminolevulinate-based gel for fluorescence detection of non-muscle invasive bladder cancer (NMIBC) during cystoscopy procedures; Metvix, a topical cream for photodynamic therapy in treating actinic keratosis, basal cell carcinoma, and low-grade squamous intraepithelial lesions of the cervix; and related diagnostic and therapeutic solutions leveraging hexaminolevulinate (HAL) technology. These products enable improved visualization and targeted treatment of precancerous and cancerous lesions, primarily serving urologists, dermatologists, gynecologists, and healthcare providers in the medical diagnostics and therapeutics sectors. Founded in 1993 and headquartered in Oslo, Norway, Photocure operates globally across Europe, North America, and Asia-Pacific markets, with a focus on urology, dermatology, and gynecology segments. The company markets its portfolio through partnerships with distributors and pharmaceutical collaborators, targeting hospitals, clinics, and specialized medical centers. Subsidiaries and international operations support its expansion in key regions including the United States, European Union countries, and select emerging markets. In the past 1-2 years, Photocure has advanced its pipeline with regulatory approvals for expanded Cevira indications and launched clinical trials for new HAL-based applications in oral lesions and other dermatological conditions. The company secured a strategic distribution alliance with a major U.S. urology partner in 2024 to broaden Cevira adoption and completed a NOK 150 million funding round to fuel R&D and commercialization efforts. Additionally, Photocure reorganized its commercial team to prioritize high-growth markets amid a shift toward combination therapies with immune checkpoint inhibitors.